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ABSTRACT

Formation of stable secondary structures by oligomers that mimic natural peptides is a key asset
for enhanced biological response.

3-Peptides with an additional methylene group in their

backbone are proteolytically stable and fold into stable 14-helical structures in solution. Here we
show that oligomeric 3-hexapeptides synthesized from L-aspartic acid monomers (3-peptides 1,
5a and 6) or homologated 3-amino acids (3-peptide 2), fold into similar stable 14-helical
secondary structures in solution, except that the former form right-handed 14-helix and the later
form left-handed 14-helix. 3-Peptides from L-Asp monomers contain an additional amide bond
in the side chains that provides opportunities for more hydrogen bonding. However based on the
NMR solution structures, we found that 3-peptide from L-Asp monomers (1) and from
homologated amino acids (2) form similar structures with no additional side chain interactions.
These results suggest that the 3-peptides derived from L-Asp are promising peptide-mimetics that
can be readily synthesized using L-Asp monomers as well as the right-handed 14-helical
conformation of these 3-peptides (such as 1 and 6) may prove beneficial in the design of mimics
for right-handed -helix of -peptides.
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INTRODUCTION
Peptidomimetic molecules play a key role in improving the biological response of peptides by stabilizing their secondary structure and increasing stability toward proteolysis.1-3 For
instance, peptide performance has been improved through partial or total replacement of α-amino
acids with β-amino acids to give /-peptide or -peptides, respectively.4-13 β3-amino acids
obtained from homologation of -amino acids (3-homo-amino acids)14 or from L-Asp monomers
(3-amido-amino acids, Scheme 1)15,16 are used for the synthesis of β3-peptides. β3-amino acids
obtained from L-Asp monomers contain an additional amide group in the side chain and therefore
are called 3-amido-amino acids.
β3-Peptides prepared from 3-homo-amino acids form a characteristic 14-helix secondary
structure in solution. Several strategies have been developed to stabilize the 14-helical secondary
structure of 3-peptides, especially in aqueous environments. Some of these strategies include salt
bridge or lactam formation between complementary charged i/i+3 side chains, as well as
introduction of cyclic residues.17-21

Formation of stable secondary structure in membrane

mimicking solvents such as 2,2,2-trifluoroethanol (TFE) is also important as several peptides act
on membrane-bound protein receptors. We previously found that a β3-hexapeptide (1) synthesized
from L-Asp monomers formed a stable right handed 14-helix in TFE,22 and replacement of three
-amino acids with β3-amido amino acids in a -decapeptide led to the discovery of  hydrid
peptides that were proteolytically stable and displayed better binding to breast cancer cells
compared to the native -peptide.8 Based on these findings and the ease of synthesis,15 we set out
to explore the folding behavior, in particular 14-helix formation, in 3-peptides derived from L-Asp
monomers.
3

RESULTS AND DISCUSSION
Design and synthesis of 3-peptide 1 analogues. Seven new analogues of 3-peptide 1 (Figure
1, 3-6) were designed to study the folding behavior of 3-peptides derived from L-Asp monomers
in TFE and aqueous conditions. 3-Peptide 1 is a hexapeptide that forms two turns of the 14-helix
in TFE, and is unstructured in aqueous conditions.22 3-Peptide 1 analogues (3-peptides 3-6) were
designed to study the minimum length required for 14-helical structure and the effect of salt-bridge
forming side chains in stabilizing the 14-helical conformation. A 3-hexapeptide 2 constructed
from 3-homo-amino acids, with the same side chains as 3-peptide 1, was included in the study
for comparison.
The smallest sequences, 3-peptides 3a and 3b, were four-residues long to incorporate one
turn of the 14-helix. 3-Peptides 4 and 5 were 5-mer and 6-mer, respectively, and each of these
contained an amino and a carboxylate side chain at positions i and i+3 for potential salt bridge
formation in the 14-helical conformation. For all the sequences, the side chains with amine groups
were either a mimic of Lysine (a analogues) or Ornithine (b analogues). Different lengths of the
side chain amine were used to study the effect of side chain length in the formation of ion-pair
interaction, as side chain lengths can affect the salt-bridge stability in helical conformations in
aqueous environments. Finally, 3-hexapeptide 6 with two amino side chains and two carboxylate
side chains at positions i and i+3 relative to each other was designed to maximize intramolecular
salt-bridge interaction and folding. In all peptides, at least one side of the helix is covered by
aliphatic side chains to allow for intramolecular hydrophobic interactions.
3-Peptides 3-6 were synthesized on the Rink amide MBHA resin essentially following the
same procedure as reported for 3-peptide 1, whereas3-peptide 2 was synthesized by coupling
4

commercially available Fmoc-3-homo-amino acids to the Rink amide resin. 3-Peptides 3-6 were
synthesized using orthogonally protected Fmoc-L-Asp monomers or pre-synthesized Fmoc-3amido-amino acids.
The general structure of Fmoc-3-amido-amino acids is shown in Scheme 1. Monomeric
Fmoc-3-amido-amino acids, such as Fmoc-β3amV-OH and Fmoc-β3amL-OH (Figure S1,
supporting information), were prepared using either solid phase or solution phase synthesis as
shown in Scheme 1. Fmoc-β3amK(Boc)-OH and Fmoc-β3amE(tBu)-OH were prepared using solid
phase synthesis method only and were obtained in 50-52% yields. The solution phase method gave
much higher yields (80%) compared to the solid phase method (50-64%). All 3-amino acids were
characterized by NMR and mass spectrometry, and the purity was assessed by analytical HPLC
(Figure S1).
Shorter sequences, 3 and 4, were synthesized by coupling orthogonally protected Fmoc-LAsp where the side chain was introduced during the SPPS, while the synthesis of hexapeptides 5
and 6, utilized pre-synthesized monomeric Fmoc-3-amido-amino acids. The completed peptide
sequences were cleaved from the resin followed by purification using RP-HPLC prior to
characterization by NMR spectroscopy, mass spectrometry and analytical HPLC (Tables S1-S9
and Figure S2). All peptides were obtained in good yields (>50%).
Protected 3-amino acids building blocks (from L-Asp) were prepared to determine if the
overall yield of long 3-peptides can be increased. Peptides 5 and 6 were obtained in relatively
high yields (81-90%) due to the use of 3-amido amino acid monomers (or protected 3-amino
acids building blocks) instead of orthogonally protected L-Asp.
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Circular dichroism spectroscopy of β3-peptides in TFE and aqueous conditions. The solution
conformation of 3-peptides was evaluated in TFE and water using CD spectroscopy. The CD
spectra provide an initial estimate of solution conformation in a relatively short time based on the
intensity of a negative minimum at 214 nm. A minimum at 214 nm for 3-peptides is considered
as a signature for 14-helical conformation and the intensity of the peak is correlated with the 14helical content.
First we compared the 14-helical folding of the five hexapeptides in TFE, a helixstabilizing solvent.23,24. As shown in Figure 2a, the mean residue ellipticity (MRE) values at 214
nm were significantly different for the five 3-peptides. Surprisingly, 1 shows the largest minima
at 214 nm (θ = -20 x 103) suggesting highest helical structure followed by 3-peptide 6 with the
next largest minimum (θ = -16 x 103). The intensity of peaks for hexamers 5a and 5b was on the
lower side with 5a (lysine side chain) showing better 14-helicity compared to 5b (ornithine side
chain) suggesting that the length of the side chain forming salt-bridge does have an effect on
folding, and the salt bridge between Lys and Glu is more stable than that between Orn and Glu.
This trend is similar to what was observed by Luc Brunsveld and coworkers in a systematic study
of side-chain to side-chain interacting 3-peptides. The authors found that in general longer side
chain lengths (β3-homoLys vs. β3-homoOrn and β3-homoGlu vs. β3-homoAsp) displayed slightly
better salt bridge stabilization and 14-helix formation.20 In a previous survey on the preferred
partner for intra--helical salt bridges in proteins of known structure, it was found to that Glutamate
not aspartate was the preferred partner suggesting that longer side chain lengths lead to better ionpair interaction and folded structure.25
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3-Peptide 2 also displays a minimum at 214 nm suggesting 14-helix conformation. The
MRE values of 3-peptide 2 and other hexamers may not be directly comparable as these have very
different side chains. Moreover, it is interesting to note that even though the absolute configuration
at 3 carbon in 3-peptides derived from homo-amino acids and L-Asp is opposite, both 3-peptides
(for instance 1 and 2) have the same sign in the minimum at 214 nm attributed to 14-helix in the
CD spectra. Most likely this is due to the major contribution from side chain amides in 3-peptides
prepared from L-Asp monomers. These peptides can be viewed as -peptides with substituted Lasparagine residues. Interestingly, Mathews et al26 observed that the CD spectrum of a fully
protected 3-hexapeptide, (Boc-[-Asp(OBn)-3-HGlu(Obn)-3-HSer(OBn)]2-OTCE, made from
L-Asp,

homo-Glu, and homo-Ser residues showed an intense maximum at 198 nm, and two

shoulders (maxima) at 207 and 216 nm suggesting opposite handed helical structure compared to
3-hexapeptides 1, 5 and 6.
Next we compared the 14-helix stability of the two hexamers, (3-peptide 5a and 6) that
engage in intramolecular salt-bridge interaction, with deceasing TFE concentration (Figures 2b
and 2c). For both the peptides, a decrease in the minimum at 214 nm was observed with increase
in water concentration suggesting a loss of helical conformation. 3-Peptide 5a always maintained
14-helical conformation (20-100% TFE), except in 100% water. A minimum at 214 nm was
observed even in 20% TFE (θ = -5 x 103) and the peak was lost only in water. 3-Peptide 6
displayed similar behavior to that of 5a in TFE/water mixtures (Figure 2c). The CD spectra of 3peptide 6 in 100% and 50% TFE show characteristic minima at 214 nm with MRE values -16 x
103 and -12 x 103, respectively. There is about 25% reduction in the helical content in 50%
TFE/water compared to 100% TFE. The spectra show very small peaks in PBC buffer (pH 7.4, 1
7

mM) and only a small shoulder in water suggesting a dramatic decrease in the helical content. The
CD spectrum for 6 was performed in PBS buffer at pH 7.4 to ensure that all amine side chains are
protonated and the carboxylate are deprotonated to enhance salt bridge interactions. However, the
peptide was definitely less folded in aqueous conditions despite the presence of two ion-pair
interactions. The loss of secondary structure in water could be due to the placement of the charged
amino acids opposite to the macrodipole. Macrodipole present in 3-peptides stabilizes secondary
structures19,27,28 and can be maintained by placing basic amino acids such as Lysine and Ornithine
near the N-terminus and acidic residues such as Aspartic and Glutamic acid near the Cterminus.19,20 Nevertheless, 3-peptide 6 forms a stable 14-helix in TFE. The CD spectra of 3peptide 6 at two different concentrations, 200 M and 1 mM, showed similar minima at 214 nm
and were found to be independent of concentration suggesting that no changes in aggregation state
occur in this concentration range. Finally, the CD spectra of 4-mer and 5-mer 3-peptides (3 and
4) suggested less folded structures compared to the hexamers (Figure S3), and did not show a clear
signature of 14-helical content. For such short oligomers, NMR spectroscopy would be required
for further evaluation of the folded conformation.

NMR solution structure studies of β3-peptides. To probe the secondary structure of 3-peptides
1 (previously studied), and 2-6 (Figure 1) in solution, a detailed NMR spectroscopic investigation
was carried out. 1D NMR of all the eight peptides (2-6) in TFE-d2 (CF3CD2OH) was examined,
and the presence of a regular secondary structure was indicated by a large dispersion of the
chemical shifts. The well dispersed chemical shifts in the amide region allowed assignment of all
the backbone and side chain protons (see supporting information, Tables S2-S9).
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A two-

dimensional (2D) NOESY experiment was performed for all the peptides, which allowed
observation of NOEs between protons from residues that are not sequentially adjacent.
Characteristic 14-helical peaks were observed mainly for 3-peptides 1, 2 and 6. The NOESY
spectrum of 3-hexapeptide 2 showed multiple (five out of six possible) long range Hi Hi+3
(Figure S4a). Whereas for 3-peptide 6, all possible (six) long range Hi Hi+3 NOEs were
observed (Figure S4b) suggesting helical conformation in these peptides. Interestingly, the
characteristic H1 H4 peaks were also observed for the smallest 4-mer 3-peptide 3a suggesting
helical conformation (Figure S4b). These peaks are a hallmark of 14-helical secondary structure.
The extent of helical folding in different -peptides can be compared using NOE data. At
least four NOE patterns involving backbone and side chain protons that are suggestive of a 14helix can be compared. These NOE patterns are NHi Hi+3, NHi Hi+2, Hi Hi+3, and the
sidechain CH2-i  sidechain NHi+3 (or Hi HSi+3). As shown in Figure 3, direct comparison of
these NOEs showed that 3-peptides 1, 2, and 6 have comparable helical conformation in solution
(TFE). Despite the presence of two pairs of oppositely charged side chains in 3-peptide 6, the
NOEs between the side chain protons of the Glu1-Lys4 and Glu2-Lys5 pairs were relatively weak,
suggesting that adoption of a stable conformation is not driven by formation of salt-bridges. The
backbone NOEs, such as for H11 H4 and H12 H4, were much stronger. Peptide 5a, with
a single pair of oppositely charged side chains, seems to be the least structured out of the four
hexapeptides as it showed only two of the Hi Hi+3 NOEs.
These peptides behaved differently in aqueous conditions. 2D NOESY and TOCSY spectra
were recorded for 3-peptide 6 in 25 mM phosphate buffer at pH 6.1 and 6.6. There was little
chemical shift dispersion, therefore hall mark long-range NOEs for 14-helices could not be
9

identified. This lack of dispersion suggests that the peptide is not (stably) folded. All the backbone
amides, H and H peaks were overlapped. The -Leu and -Lys side chain shifts were exactly
overlapped. The -Glu side chain protons had slightly different shifts. This may be due to the fact
that one of the -Glus is the N-terminal residue. These observations agreed with the CD data as
the characteristic minima for 14-helix was not observed for the peptides in aqueous conditions.
The NMR data suggests that the peptides were not aggregated in water as line widths were
comparable to those observed in the spectra recorded in TFE.
The three-dimensional structures of 1 (done previously), 2 and 6 were obtained using the
NOE data and the program CYANA.

29

The input data and structure calculation statistics of

peptides 2 and 6 are summarized in Tables S10 and S11. The pdb coordinates of the 20 structures
obtained from CYANA program were averaged to obtain the final peptide structures in TFE
(Figure 4). 3-hexapeptides 1 and 6 form a right-handed 14-helical structure with a radius of 2.6
Å and 4.69 Å rise/turn. In contrast, the 3-hexapeptide 2 made up of homo-amino acids, forms a
left-handed 14-helix (Figures 5 and S5). The difference in the conformation of the two helices
(right-handed versus left-handed) could be due to the opposite stereochemistry at the 3 carbon in
the peptide backbone. The radius and the pitch for the two helices are found to be similar.
The extra amide bond in the side chain of 3-peptides derived from L-Asp monomers
provides opportunities for additional hydrogen bonding capabilities and perhaps unprecedented
secondary structures. However, we found that the side chain amide bonds in these 3-peptides (1,
5a, and 6) do not seem to interact much except that for 3-peptide 1 we see a Leu3 side chain O
to Leu6 side chain N hydrogen bond possible in some structures. All possible NOEs were
incorporated into the structure calculations, and clearly there were not enough contacts observed
10

between the i and i+3 side chains to constrain them in a way to give consistent hydrogen bonds in
the side chains.

CONCLUSIONS
In summary, we show that 3-peptides can readily be synthesized from L-Asp monomers
and for the first time compare the solution conformation of 3-peptides synthesized from 3homoamino acids and L-Asp monomers. Both 3-peptides form similar 14-helix structure which
can be stabilized by salt-bridge interactions of the side chains at i and i+3 positions in conjunction
with a maintained helix macrodipole. The 3-hexapeptides reported here with the charged side
chains (5 and 6) at i and i+3 positions, however, did not have the basic and acidic side chains in
the correct order to stabilize the helix macrodipole and therefore, did not give stable structures
compared to the 3-peptide with no salt-bridge interaction (3-peptide 1). The synthesis of 3peptides with charged residues that will maintain the helix macrodipole is currently in progress.
The findings presented here show that 3-peptides derived from L-Asp will facilitate the design
and development of peptidomimetics with improved biological properties.

MATERIALS AND METHODS
Solvents and reagents. Rink amide methylbenzhydrylamine (MBHA) resin (0.58 mmol/g), 2chlorotrityl chloride resin (1.4 mmol/g), N-α-Fmoc-L-aspartic acid α-allyl ester, Fmoc-Asp(OtBu)OH, Boc-L-asparagine, Fmoc-3hLeu-OH, Fmoc-3hLys(Boc)-OH, Fmoc-3hVal-OH, tert-butyl
N-(4-aminobutyl)carbamate, β-alanine t-butyl ester hydrochloride, 1-hydroxybenzotriazole
(HOBt), and benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
11

(BOP) were purchased from NovaBiochem (San Diego, CA). Isobutylamine, isopropylamine,
dimethylformamide (DMF), N-methyl morpholine (NMM), trifluoroacetic acid (TFA), and all
other reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).

Piperidine was

purchased from Caledon. All commercial reagents and solvents were used as received. Silica gel
for column chromatography was obtained from Rose Scientific Ltd. Column chromatography was
performed under slight positive air pressure using silica gel 60 (70-230 mesh).

Equipment. RP-HPLC purification and analysis were carried out on a Waters (625 LC system)
HPLC system using auto-injector mode or Varian Prostar HPLC system (Walkersville, MD, USA)
using manual injector. Vydac C18 semi-preparative (1 x 25 cm, 5 μm) and analytical (0.46 x 25
cm, 5 μm) columns were used. Peptides were detected by UV absorption at 220 nm. Mass spectra
were recorded on a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)
Voyager spectrometer (VoyagerTM Elite) or Waters micromass ZQ (Waters Corp., Milford, MA,
USA) mass spectrometer. CD measurements were made on an olis CD spectrometer (Georgia,
USA) at 25 °C in a thermally controlled quartz cell (Hellma, Plainview, NY). NMR experiments
were recorded on a Bruker AM-300 spectrometer at the Faculty of Pharmacy and Pharmaceutical
Sciences (University of Alberta), or on a Varian INOVA 500 MHz NMR spectrometer equipped
with a triple-resonance HCN Cold Probe with z-axis pulsed field gradients at the Quebec/Eastern
Canada High Field NMR Centre, McGill University, Montreal, Quebec. pH measurements for all
buffer solutions were done at 25 °C with a digital SB20 Symphony VWR pH meter using a
calibration buffer set (Fluka).
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Peptide Synthesis. The synthesis of 3-peptide 1 has been reported previously15 and eight 3peptides (2-6) were synthesized following the manual Fmoc-solid phase peptide synthesis. The
crude peptides were cleaved from the resin by treatment with TFA:TIPS:H2O (96:2:2) cocktail
mixture with stirring for 2 h. The crude peptides were purified using semi-preparative RP-HPLC
prior to characterization by electrospray and/or MALDI-TOF mass spectrometry and analytical
HPLC (Table S1 and Figure S2). All eight peptides were also characterized by 1D proton NMR
(Tables S2-S9).
3-Peptide 2 was synthesized by coupling Fmoc-3h-amino acids (Fmoc-3hLeu-OH,
Fmoc-3hLys(Boc)-OH or Fmoc-3hVal-OH) sequentially to the Rink amide MBHA resin using
BOP and HOBt as coupling reagents. The syntheses of 3-peptides 3 and 4 followed the same
procedure as reported for 3-peptide 1 using orthogonally protected Fmoc-L-aspartic acid.15
Briefly, orthogonally protected L-aspartic acid (Nα-Fmoc-L-aspartic acid α-allyl ester) is coupled
to the Rink amide MBHA resin using BOP with HOBt. The side chain allyl group is first removed
with Pd(PPh3)4 followed by coupling with an amine (for the corresponding side chain). Next the
Fmoc group is removed and orthogonally protected L-aspartic acid is coupled to follow the next
cycle till the sequence is complete.
The synthesis of 3-peptide 5 was accomplished by coupling monomeric Fmoc-3-amidoamino acid (Nβ-Fmoc-β3amV-OH) to 3-peptide 4. For 3-peptide 6, orthogonally protected Laspartic acid was coupled to introduce the first two amino acids, and the last four residues were
coupled as monomeric Fmoc-3-amido-amino acids to complete the sequence. Monomeric Fmoc3-amido-amino acids (Fmoc-β3amV-OH, Fmoc-β3amL-OH, Fmoc-β3amK(Boc)-OH, and Fmoc-
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β3amE(tBu)-OH) were synthesized using solid phase or solution phase synthesis as described
below.

Solid Phase Synthesis of Fmoc-3-Amido-Amino Acid Monomers. Orthogonally protected β3amido amino acid monomers were synthesized in four steps as shown in Scheme 1. In a solid
phase reactor, chlorotrityl resin (74 mg, 0.1 mmol) was suspended in CH2Cl2 (4 mL) for swelling
for 30 min. The swelled resin was reacted with a solution of Fmoc-L-aspartic acid α-allyl ester
(118.6 mg, 3 equiv) and DIPEA (210 μL, 12 equiv) in dry CH2Cl2 for 2 h. The resin was capped
by washing with a solution of dry CH2Cl2–MeOH–DIPEA (17:2:1). The resin was washed with
DMF (4 x 1 min), DCM (4 x 1 min) and IPA. Deallylation was carried out in the presence of
Pd(PPh3)4 (0.08 equiv) and PhSiH3 (8 equiv) in DCM (3 x 35 mins) under nitrogen to remove the
side chain allyl protection. Subsequently, the side chain amine (2.5 equiv) was coupled using BOP
(110 mg, 2.45 equiv), HOBt (33 mg, 2.5 equiv), and NMM (75 uL, 4.5 equiv) in DMF for 5 h.
Cleavage of the monomer from the resin was done either by treating with 50% TFA/DCM for 30
min, or with TFE/DCM (20/80%) for 45 min at room temperature.

Synthesis of Nβ-Fmoc-β3amV.

Nβ-Fmoc-β3amV-OH was synthesized using the procedure

described above. Isopropylamine was coupled after removal of side chain allyl group and the final
product was cleaved from the resin using 50% TFA/DCM for 30 min. The residue was added to
cold Et2O (40 mL, -78 °C) and centrifuged at 3,500 rpm for 5 min. The Et2O was decanted and the
pellet was resuspended in cold Et2O (40 mL, -78°C) and centrifugation was repeated three times.
Again the Et2O was decanted and the pellet was dried with N2 with an overall yield 65%. The purity
was assessed by analytical HPLC as shown in Figure S1. 1H NMR (300 MHz, CD3OD): δ= 1.06
14

(d, J= 6.7, 6H, (CH3)2CH), 2.6 (m, 2H, CH2COOH), 3.94 (m, 1H, (CH3)2 CH), 4.25 (m, 1H,
CHCH2O), 4.7 (m, 2H, CHCH2O), 4.6 (t, 1H, CHCH2COOH), 7.2-7.8 (m, 8H, aryl H).
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C NMR

(300 MHz, DMSO-d6, CD3OD): δ= 19.93, 40.67, 40.76, 46.51, 50.68, 65.50, 119.76, 124.99,
126.80, 127.35, 140.52, 143.57, 155.56, 168.8, 172.87, and ES-MS: Calcd. for C22H24N2O5,
[M+H]+ 397.47; found [M+H]+ 397.06.

Synthesis of Nβ-Fmoc-β3amL.

The synthesis of Nβ-Fmoc-β3amL-OH followed the same

procedure as for Nβ-Fmoc-β3amV-OH, except that isobutylamine was coupled after removal of
side chain allyl group with an overall yield of 63%. The purity was assessed by analytical HPLC
as shown in Figure S1. 1H NMR (300 MHz, CDCl3): δ= 0.96 (d, J=6.6, 6H, (CH3)2CH), 1.85 (m,
1H, (CH3)2 CH), 2.8 (m, 1H, CH2COOH), 2.9 (m, 1H, CH2COOH), 3.2 (m, 2H, (CH3)2
CH)CH2NH), 4.2 (m, 1H, CHCH2O), 4.45 (m, 2H, CHCH2O, CHCH2COOH), 7.2-7.8 (m, 8H,
arylH).
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C NMR (300 MHz, CDCl3): δ= 19.93, 27.9, 36.9, 46.06, 46.51, 50.68, 65.60, 119.76,

124.99, 126.8, 127.35, 140.52, 143.57, 155.56, 168.87, 172.8, and ES-MS: Calcd. for C23H26N2O5,
[M+H]+ 411.47; found [M+H]+ 411.00.

Synthesis of Nβ-Fmoc-β3amK(Boc)-OH. Nβ-Fmoc-β3amK (Boc)-OH was synthesized using the
same procedure as described above. The side chain mimicking lysine was introduced by coupling
with tert-butyl N-(4-aminobutyl)carbamate after allyl group removal. Nβ-Fmoc-β3amK (Boc)-OH
was cleaved from the resin using TFE/DCM (2:8) for 45 min to obtain the monomer with an overall
of yield 52%. The purity was assessed by analytical HPLC as shown in Figure S1. 1H NMR (300
MHz, CDCl3): δ=1.3 (m, 13H, (CH3)3 CH (CH2)2), 2.2-2.4 (m, 2H, CH2COOH), 2.7- 3.1 (m, 4H,
(NH)CH2 CH2 CH2 CH2NH), 3.7 (m, 4H, CHCH2O, 2H, CHCH2O, CHCH2COOH), 7.2-7.8 (m,
15

8H, aryl H).
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C NMR (300 MHz, CD3OD):  = 26.34, 26.83, 28.26, 40.69, 40.98, 51.04, 77.30,

119.98, 121.10, 122.17, 123.88, 127.68, 128.88, 129.43, 135.33, 137.36, 139.34, 142.50, 155.52,
170.93, and ES-MS: Calcd. C28H35N3O7, [M-H]- 524.25; found [M-H]- 524.

Synthesis of Nβ-Fmoc-β3amE(tBu)-OH: Nβ-Fmoc-β3amE(tBu)-OH (10) was synthesized using
the same procedure as described above for Nβ-Fmoc-β3amK (Boc)-OH. The side chain mimicking
glutamic acid was introduced by coupling with β-alanine t-butyl ester hydrochloride after allyl
group removal. The overall yield was found to be 50%, and the purity was assessed by analytical
HPLC as shown in Figure S1. 1H NMR (300 MHz, d-DMSO): δ= 1.4 (s, 9H, (CH3)3C), 2.5-2.8
(m, 4H, CH2COOH, CH2CH2NHCO), 3.6 (m, 2H, CH2CH2NHCO), 4.25-4.4 (m, 4H, CHCH2O,
CHCH2O, CHCH2COOH), 7.3-7.8 (m, 8H, aryl H). 13C NMR (300 MHz, d-DMSO): δ=27, 34.88,
34.98, 40.34, 46.64, 50.53, 65.77, 79.99, 120.14, 125.28, 127.13, 127.42, 127.68, 140.7, 143.80,
155.82, 170.76, 171.69, 173.04, and ES-MS: Calcd. for C26H30N2O7, [M-H]- 481.54; found [MH]- 481.20.

Solution Phase Synthesis of Fmoc-3-Amido-Amino Acid Monomers. β3-am-Val and β3-amLeu monomers were also synthesized using solution phase synthesis as illustrated in Scheme 1.
Fmoc-Asp(OtBu)-OH (412 mg, 1 mmol), BOP (442 mg, 1.95 equiv) , HOBt (135 mg, 2 equiv)
and NMM (200 μL, 4.5 equiv) were weighted into a round bottom flask, and dissolved in
DMF/DCM (4 mL). The mixture was stirred for 5 min to activate the carboxyl group, following
which the amine side chain (isopropylamine or isobutylamine, 5 equiv) was added and the reaction
mixture was stirred for 24 h at room temperature. The completion of reaction was monitored using
TLC. The reaction mixture was evaporated to give oil as the residue. The residue was dissolved
16

in EtOAc (10 mL). The EtOAc was washed with 5% NaHCO3 three times followed by washing
(3x) with brine (0.9% NaCl solution). The organic layer was then dried (Na2SO4), filtered, and
concentrated. The product was characterized using mass spectrometry. After confirmation of the
mass, the precipitate was treated with TFA:TIPS:H2O (96:2:2) cocktail mixture with stirring for 2
h. The reaction mixture was then evaporated under vacuum and the product was washed several
times with diethyl ether.

The precipitate obtained was further characterized with mass

spectrometry, HPLC, and NMR spectroscopy. The overall yield was 80.5%. The product was
used without further purification.

Circular Dichroism. All CD measurements were made on an Olis CD spectrometer (Georgia,
USA) at 25 °C in 2 mm path length thermally controlled quartz cell, over 190-260 nm. All samples
were prepared in the appropriate solvents immediately prior to recording the spectra (TFE, H2O,
or PBS).

Spectra represent the average of five scans, and were background-corrected and

smoothed. Each peptide was analyzed at concentrations of 100, 200, 250, and 500 μM. Peptide
concentrations were determined using dry weight of the lyophilized peptide. Spectra were
normalized to mean residue ellipticity (deg cm2 dmol-1) using the formula A*M*3298/ (L*C),
where C is concentration in g/L, M is average molecular weight (g/mol), L is path length of the
cell.30

Two-dimensional NMR and Structure Elucidation of β3-Peptides 2 and 6. All 2D NMR
measurements and structure elucidation was done at Quebec/Eastern Canada High Field NMR
Centre, McGill University, Montreal, Quebec. A 1.5 mM sample of peptides 2 or 6 in 100% TFEd2 (CF3CD2OH) (Cambridge Isotope Laboratories, Inc.) was prepared for 2D NMR experiments.
17

Sequence specific assignments were established by following the procedures used for -amino acid
peptides.31 2D TOCSY (60 ms mixing time), COSY and NOESY (mixing time 300 ms) spectra
were recorded at 10 C on a Varian INOVA 500 MHz spectrometer. The upper distance restraints
for 2 and 6 were obtained from a 300 ms mixing time 2D-NOESY recorded at 10 C on a Varian
INOVA 800 MHz NMR spectrometer, equipped with an HCN cold probe and pulsed-field
gradients. Calculation of the complete three-dimensional structure was performed with the
program CYANA v2.29 The structure calculation statistics for 2 and 6 are summarized in Tables
S10 and S11, respectively. The final calculations were started with 200 randomized conformers
all of which converged to the helical conformation (average backbone RMSD to mean for 200
structures: 0.54 ± 0.10 Å for 3-peptide 2 and 0.50 ± 0.12 Å for 3-peptide 6). A bundle of the 20
lowest energy CYANA conformers were used to represent the NMR structures of 2 and 6 (Figure
4).

SUPPORTING INFORMATION
Peptide characterization and data for three-dimensional NMR solution structures of 2 and 6.

ACKNOWLEDGEMENTS
This work was supported by the Natural Sciences and Engineering Research Council of Canada
(NSERC).

References
(1)

Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. Chemical Reviews 2001, 101, 3219-3232.

18

(2)

Goodman, C. M.; Choi, S.; Shandler, S.; DeGrado, W. F. Nature Chemical Biology 2007,

3, 252-262.
(3)

Seebach, D.; Beck, A. K.; Bierbaum, D. J. Chemistry & Biodiversity 2004, 1, 1111-1239.

(4)

Denton, E. V.; Craig, C. J.; Pongratz, R. L.; Appelbaum, J. S.; Doerner, A. E.; Narayanan,

A.; Shulman, G. I.; Cline, G. W.; Schepartz, A. Org Lett 2013, 15, 5318-5321.
(5)

English, E. P.; Chumanov, R. S.; Gellman, S. H.; Compton, T. J Biol Chem 2006, 281,

2661-2667.
(6)

Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S.

H. Proc Natl Acad Sci U S A 2009, 106, 14751-14756.
(7)

Kritzer, J. A.; Zutshi, R.; Cheah, M.; Ran, F. A.; Webman, R.; Wongjirad, T. M.; Schepartz,

A. Chembiochem 2006, 7, 29-31.
(8)

Soudy, R.; Gill, A.; Sprules, T.; Lavasanifar, A.; Kaur, K. J Med Chem 2011, 54, 7523-

7534.
(9)

Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. J Am Chem Soc 2004, 126, 9468-

9469.
(10)

Raguse, T. L.; Porter, E. A.; Weisblum, B.; Gellman, S. H. J Am Chem Soc 2002, 124,

12774-12785.
(11)

Kolesinska, B.; Podwysocka, D. J.; Rueping, M. A.; Seebach, D.; Kamena, F.; Walde, P.;

Sauer, M.; Windschiegl, B.; Meyer-Acs, M.; Bruggen, M. V. D.; Giehring, S. Chemistry &
Biodiversity 2013, 10, 1-38.
(12)

Lee, E. F.; Smith, B. J.; Horne, W. S.; Mayer, K. N.; Evangelista, M.; Colman, P. M.;

Gellman, S. H.; Fairlie, W. D. Chembiochem 2011, 12, 2025-2032.

19

(13)

Smith, B. J.; Lee, E. F.; Checco, J. W.; Evangelista, M.; Gellman, S. H.; Fairlie, W. D.

Chembiochem 2013, 14, 1564-1572.
(14)

Seebach, D.; Overhand, M.; Kuhnle, F. N. M.; Martinoni, B.; Oberer, L.; Hommel, U.;

Widmer, H. Helvetica Chimica Acta 1996, 79, 913-941.
(15)

Ahmed, S.; Beleid, R.; Sprules, T.; Kaur, K. Org Lett 2007, 9, 25-28.

(16)

Ahmed, S.; Kaur, K. Chemical Biology & Drug Design 2009, 73, 545-552.

(17)

Arvidsson, P. I.; Rueping, M.; Seebach, D. Chemical Communications 2001, 649-650.

(18)

Guarracino, D. A.; Chiang, H. J. R.; Banks, T. N.; Lear, J. D.; Hodsdon, M. E.; Schepartz,

A. Org Lett 2006, 8, 807-810.
(19)

Hart, S. A.; Bahadoor, A. B. F.; Matthews, E. E.; Qiu, X. Y. J.; Schepartz, A. J Am Chem

Soc 2003, 125, 4022-4023.
(20)

Vaz, E.; Dames, S. A.; Geyer, M.; Brunsveld, L. Organic & Biomolecular Chemistry 2012,

10, 1365-1373.
(21)

Vaz, E.; Pomerantz, W. C.; Geyer, M.; Gellman, S. H.; Brunsveld, L. Chembiochem 2008,

9, 2254-2259.
(22)

Kaur, K.; Sprules, T.; Soliman, W.; Beleid, R.; Ahmed, S. Biochimica Et Biophysica Acta-

Proteins and Proteomics 2008, 1784, 658-665.
(23)

Fioroni, M.; Diaz, M. D.; Burger, K.; Berger, S. J Am Chem Soc 2002, 124, 7737-7744.

(24)

Roccatano, D.; Colombo, G.; Fioroni, M.; Mark, A. E. Proc Natl Acad Sci U S A 2002, 99,

12179-12184.
(25)

Sundaralingam, M.; Sekharudu, Y. C.; Yathindra, N.; Ravichandran, V. Proteins-Structure

Function and Genetics 1987, 2, 64-71.

20

(26)

Mathews, J. L.; Gademann, K.; Jaun, B.; Seebach, D. J. Chem. Soc., Perkin Trans. 1 1998,

3331-3340.
(27)

Kritzer, J. A.; Tirado-Rives, J.; Hart, S. A.; Lear, J. D.; Jorgensen, W. L.; Schepartz, A. J

Am Chem Soc 2005, 127, 167-178.
(28)

Raguse, T. L.; Lai, J. R.; Gellman, S. H. Helvetica Chimica Acta 2002, 85, 4154-4164.

(29)

Guntert, P. Methods Mol Biol 2004, 278, 353-378.

(30)

McMahon, B., Mays, D., Lipsky, J., Stewart, JA., Fauq, A., Richelson, E. Antisense

Nucleic Acid Drug Dev. 2002, 12, 65-70.
(31)

Wuthrich, K. NMR of Proteins and Nucleic Acids, Wiley, New York 1986.

21

FIGURE CAPTIONS
Figure 1. Structures of the 3-peptides used in this study. -Peptides 1, 3-6 are derived from amido residues, and -peptide 2 is synthesized from -homo residues.

Scheme 1. General pathway of solid phase (top row) and solution phase (bottom row) syntheses of
Fmoc-3-amido-amino acids from Fmoc-L-Asp.

Figure 2. Circular dichroism (CD) spectra for 3-hexapeptides (200 M) at 25 ºC showing (a) 1,
2, 5a, 5b, and 6 in TFE, (b) 5a in TFE, TFE/water, and aqueous solution, and (C) 6 in TFE,
TFE/water, aqueous media, and PBC buffer (pH 7.4).

Figure 3. A comparison of the NOE of β3-hexapeptides 1, 2, 5a and 6 (in TFE) are summarized. *
denotes amide protons not observed due to exchange with solvent and X stands for H protons not
observed due to overlap with solvent signal. Grey lines indicate ambiguous assignments.

Figure 4. 3D NMR solution structures of -peptides 2 and 6 in TFE. The top view of the helices
are shown using stick model (LHS) and overlay of 10 calculated structures (RHS) for 2 (a-b) and
6 (c-d).

Figure 5. Solution conformation of -hexapeptides 1 and 2 in TFE showing right-handed 14helix for 1 and left-handed 14-helix for 2. -Peptide 1 has an additional amide group in each side
chain.
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Figure 1. Structures of the 3-peptides used in this study. -peptides 1, 3-6 are derived from amido residues, and -peptide 2 is synthesized from -homo residues.
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Scheme 1. General pathway of solid phase (top row) and solution phase (bottom row) syntheses of
Fmoc-3-amido-amino acids from Fmoc-L-Asp.
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Figure 2. Circular dichroism (CD) spectra for 3-hexapeptides (200 M) at 25 ºC showing (a) 1,
2, 5a, 5b, and 6 in TFE, (b) 5a in TFE, TFE/water, and aqueous solution, and (C) 6 in TFE,
TFE/water, aqueous media, and PBC buffer (pH 7.4).
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Figure 3. A comparison of the NOE of β3-hexapeptides 1, 2, 5a and 6 (in TFE) are summarized. *
denotes amide protons not observed due to exchange with solvent and X stands for H protons not
observed due to overlap with solvent signal. Grey lines indicate ambiguous assignments.
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Figure 4. 3D NMR solution structures of -peptides 2 and 6 in TFE. The top view of the
helices are shown using stick model (LHS) and overlay of 10 calculated structures (RHS) for 2
(a-b) and 6 (c-d).
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Figure 5. Solution conformation of -hexapeptides 1 and 2 in TFE showing right-handed 14helix for 1 and left-handed 14-helix for 2. -peptide 1 has an additional amide group in each side
chain.
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